Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 7,413 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tissue specimen Clear all

Conditions: Breast Cancer, Breast Cancer Female
Interventions: PVB Protocol, PECS-1, Serratus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Laxity (Submental and Neck), Skin Lifting and Tightening
Interventions: 2910 nm fiber laser (UltraClear®); Device
Lead sponsor: FA Corporation; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Prospect, Kentucky • Houston, Texas

Conditions: Venous Leg Ulcer (VLU)
Interventions: Amnion-Intermediate-Chorion, Standard of Care (SOC); Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rocky Mount, North Carolina

Conditions: Degenerative Disc Disease, Spondylolisthesis
Interventions: Not listed
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 15
States / cities: Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 12 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: Busulfan, Cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: TDC differential value; Diagnostic Test
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions: Endoscopic ultrasound shear wave elastography; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 74 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: San Francisco, California • Winston-Salem, North Carolina

Conditions: Sciatica Acute, Sciatica Pain
Interventions: Ultrasound guided transgluteal sciatic nerve hydrodissection; Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: COPD, Interstitial Lung Disease
Interventions: Cell therapy; Procedure
Lead sponsor: Lung Institute; Industry
Eligibility: 16 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leukemia, Lymphoma
Interventions: fludarabine phosphate, Cyclophosphamide, PBSC, G-CSF, Donor lymphocytes; Drug · Biological
Lead sponsor: Cancer and Leukemia Group B; Network
Eligibility: Up to 69 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 19
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 16 more

Conditions: Carcinoma in Situ of Uterine Cervix, Cervical Intraepithelial Neoplasias, High Grade Cervical Intraepithelial Neoplasia
Interventions: Multispectral Digital Colposcope with probe; Device
Lead sponsor: Brookdale University Hospital Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Breast Cancer
Interventions: cyclophosphamide, doxorubicin hydrochloride, paclitaxel, fluorescence in situ hybridization, immunohistochemistry staining method; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Psychosocial Effects of Cancer and Its Treatment, Therapy-related Toxicity
Interventions: exercise intervention, telephone-based intervention, dietary intervention, educational intervention, questionnaire administration, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, assessment of therapy complications, peripheral blood stem cell transplantation, psychosocial assessment and care, quality-of-life assessment, standard follow-up care; Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Duarte, California

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Disorder, Head and Neck Cancer
Interventions: Bevonescein (ALM 488) Infusion; Drug
Lead sponsor: Matthew Spector; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Embolism, Thrombophlebitis
Interventions: Recombinant Tissue Plasminogen Activator, Heparin, Warfarin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anesthesia
Interventions: One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo); Combination Product · Drug
Lead sponsor: Cetylite Industries; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Daphne, Alabama • Denver, Colorado • Pensacola, Florida + 14 more

Conditions: Hidradenitis Suppurativa
Interventions: LOU064, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Diego, California • Mayfield Heights, Ohio

Conditions: Hiatal Hernia
Interventions: SurgiMend Mesh; Device
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Uterine Fibroids
Interventions: Proellex 25 mg, Proellex 50 mg, Lupron Depot; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Sarasota, Florida • Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiosurgery; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction

Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

Advanced Materials Science in XLIF Study

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Assessing Tissue Dielectric Constant (TDC) to Differentiate Breast Cancer Breast Cancer From Healthy Breasts

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Ultrasound-guided Transgluteal Sciatic Nerve Hydrodissection for the Treatment of Sciatica in the Emergency Department

An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

A Standardized Nursing Intervention Protocol for HCT Patients

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

Treatment for Blood Clots in the Veins of the Legs

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

MYLUNG Consortium Study Protocol 2

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

SurgiMend Mesh at the Hiatus

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors